Mars Greenhouses: Concepts and Challenges. Proceedings from a 1999 Workshop

Topic covered include :Plants on Mars: On the Next Mission and in the Long Term Future; Bubbles in the Rocks: Natural and Artificial Caves and Cavities as Like Support Structures; Challenges for Bioregenerative Life Support on Mars; Cost Effectiveness Issues; Low Pressure Systems for Plant Growth; Plant Responses to Rarified Atmospheres; Can CO2 be Used as a Pressurizing Gas for Mars Greenhouses?; Inflatable Habitats Technology Development; Development of an Inflatable Greenhouse for a Modular Crop Production System; Mars Inflatable Greenhouse Workshop; Design Needs for Mars Deployable Greenhouse; Preliminary Estimates of the Possibilities for Developing a Deployable Greenhouse for a Planetary Surface Mars; Low Pressure Greenhouse Concepts for Mars; Mars Greenhouse Study: Natural vs. Artificial Lighting; and Wire Culture for an Inflatable Mars Greenhouse and Other Future Inflatable Space Growth Chambers

Crop Updates 2006 - Cereals

This session covers twenty nine papers from different authors: PLENARY 1. The 2005 wheat streak mosaic virus epidemic in New South Wales and the threat posed to the Western Australian wheat industry, Roger Jones and Nichole Burges, Department of Agriculture SOUTH COAST AGRONOMY 2. South coast wheat variety trial results and best options for 2006, Mohammad Amjad, Ben Curtis and Wal Anderson, Department of Agriculture 3. Dual purpose winter wheats to improve productivity, Mohammad Amjad and Ben Curtis, Department of Agriculture 4. South coast large-scale premium wheat variety trials, Mohammad Amjad and Ben Curtis, Department of Agriculture 5. Optimal input packages for noodle wheat in Dalwallinu – Liebe practice for profit trial, Darren Chitty, Agritech Crop Research and Brianna Peake, Liebe Group 6. In-crop risk management using yield prophet®, Harm van Rees1, Cherie Reilly1, James Hunt1, Dean Holzworth2, Zvi Hochman2; 1Birchip Cropping Group, Victoria; 2CSIRO, Toowoomba, Qld 7. Yield Prophet® 2005 – On-line yield forecasting, James Hunt1, Harm van Rees1, Zvi Hochman2,Allan Peake2, Neal Dalgliesh2, Dean Holzworth2, Stephen van Rees1, Trudy McCann1 and Peter Carberry2; 1Birchip Cropping Group, Victoria; 2CSIRO, Toowoomba, Qld 8. Performance of oaten hay varieties in Western Australian environments, Raj Malik and Kellie Winfield, Department of Agriculture 9. Performance of dwarf potential milling varieties in Western Australian environments, Kellie Winfield and Raj Malik, Department of Agriculture 10. Agronomic responses of new wheat varieties in the Southern agricultural region of WA, Brenda Shackley and Judith Devenish, Department of Agriculture 11. Responses of new wheat varieties to management factors in the central agricultural region of Western Australia, Darshan Sharma, Steve Penny and Wal Anderson,Department of Agriculture 12. Sowing time on wheat yield, quality and $ - Northern agricultural region, Christine Zaicou-Kunesch, Department of Agriculture NUTRITION 13.The most effective method of applying phosphorus, copper and zinc to no-till crops, Mike Bolland and Ross Brennan, Department of Agriculture 14. Uptake of K from the soil profile by wheat, Paul Damon and Zed Rengel, Faculty of Natural and Agricultural Sciences, University of Western Australia 15. Reducing nitrogen fertiliser risks, Jeremy Lemon, Department of Agriculture 16. Yield Prophet® and canopy management, Harm van Rees1, Zvi Hochman2, Perry Poulton2, Nick Poole3, Brooke Thompson4, James Hunt1; 1Birchip Cropping Group, Victoria; 2CSIRO, Toowoomba, Qld; 3Foundation for Arable Research, New Zealand; 4Cropfacts, Victoria 17. Producing profits with phosphorus, Stephen Loss, CSBP Ltd, WA 18. Potassium response in cereal cropping within the medium rainfall central wheatbelt, Jeff Russell1, Angie Roe2 and James Eyres2, Department of Agriculture1, Farm Focus Consultants, Northam2 19. Matching nitrogen supply to wheat demand in the high rainfall cropping zone, Narelle Simpson, Ron McTaggart, Wal Anderson, Lionel Martin and Dave Allen, Department of Agriculture DISEASES 20. Comparative study of commercial wheat cultivars and differential lines (with known Pm resistance genes) to powdery mildew response, Hossein Golzar, Manisha Shankar and Robert Loughman, Department of Agriculture 21. On farm research to investigate fungicide applications to minimise leaf disease impacts in wheat – part II, Jeff Russell1, Angie Roe2and James Eyres2, Department of Agriculture1, and Farm Focus Consultants, Northam2 22. Disease resistance update for wheat varieties in WA, Manisha Shankar, John Majewski, Donna Foster, Hossein Golzar, Jamie Piotrowski, Nicole Harry and Rob Loughman, Department of Agriculture 23. Effect of time of stripe rust inoculum arrival on variety response in wheat, Manisha Shankar, John Majewski and Rob Loughman, Department of Agriculture 24. Fungicide seed dressing management of loose smut in Baudin barley, Geoff Thomas and Kith Jayasena, Department of Agriculture PESTS 25. How to avoid insect contamination in cereal grain at harvest, Svetlana Micic, Paul Matson and Tony Dore, Department of Agriculture ABIOTIC 26. Environment – is it as important as variety in sprouting tolerance? Thomas (Ben) Biddulph1, Dr Daryl Mares1, Dr Julie Plummer1 and Dr Tim Setter2, School of Plant Biology, University of Western Australia1 and Department of Agriculture2 27. Frost or fiction, Garren Knell, Steve Curtin and Wade Longmuir, ConsultAg Pty Ltd, WA 28. High moisture wheat harvesting in Esperance 2005, Nigel Metz, South East Premium Wheat Growers Association (SEPWA) Projects Coordinator, Esperance, WA SOILS 28. Hardpan penetration ability of wheat roots, Tina Botwright Acuña and Len Wade, School of Plant Biology, University of Western Australia MARKETS 29. Crop shaping to meet predicted market demands for wheat in the 21st Century, Cindy Mills and Peter Stone,Australian Wheat Board, Melbourn

The James Webb Space Telescope Mission

Twenty-six years ago a small committee report, building on earlier studies, expounded a compelling and poetic vision for the future of astronomy, calling for an infrared-optimized space telescope with an aperture of at least $4m$. With the support of their governments in the US, Europe, and Canada, 20,000 people realized that vision as the $6.5m$ James Webb Space Telescope. A generation of astronomers will celebrate their accomplishments for the life of the mission, potentially as long as 20 years, and beyond. This report and the scientific discoveries that follow are extended thank-you notes to the 20,000 team members. The telescope is working perfectly, with much better image quality than expected. In this and accompanying papers, we give a brief history, describe the observatory, outline its objectives and current observing program, and discuss the inventions and people who made it possible. We cite detailed reports on the design and the measured performance on orbit.Comment: Accepted by PASP for the special issue on The James Webb Space Telescope Overview, 29 pages, 4 figure

Consensus statement on abusive head trauma in infants and young children

Abusive head trauma (AHT) is the leading cause of fatal head injuries in children younger than 2 years. A multidisciplinary team bases this diagnosis on history, physical examination, imaging and laboratory findings. Because the etiology of the injury is multifactorial (shaking, shaking and impact, impact, etc.) the current best and inclusive term is AHT. There is no controversy concerning the medical validity of the existence of AHT, with multiple components including subdural hematoma, intracranial and spinal changes, complex retinal hemorrhages, and rib and other fractures that are inconsistent with the provided mechanism of trauma. The workup must exclude medical diseases that can mimic AHT. However, the courtroom has become a forum for speculative theories that cannot be reconciled with generally accepted medical literature. There is no reliable medical evidence that the following processes are causative in the constellation of injuries of AHT: cerebral sinovenous thrombosis, hypoxic-ischemic injury, lumbar puncture or dysphagic choking/vomiting. There is no substantiation, at a time remote from birth, that an asymptomatic birth-related subdural hemorrhage can result in rebleeding and sudden collapse. Further, a diagnosis of AHT is a medical conclusion, not a legal determination of the intent of the perpetrator or a diagnosis of murder. We hope that this consensus document reduces confusion by recommending to judges and jurors the tools necessary to distinguish genuine evidence-based opinions of the relevant medical community from legal arguments or etiological speculations that are unwarranted by the clinical findings, medical evidence and evidence-based literature

The Somatic Genomic Landscape of Glioblastoma

We describe the landscape of somatic genomic alterations based on multi-dimensional and comprehensive characterization of more than 500 glioblastoma tumors (GBMs). We identify several novel mutated genes as well as complex rearrangements of signature receptors including EGFR and PDGFRA. TERT promoter mutations are shown to correlate with elevated mRNA expression, supporting a role in telomerase reactivation. Correlative analyses confirm that the survival advantage of the proneural subtype is conferred by the G-CIMP phenotype, and MGMT DNA methylation may be a predictive biomarker for treatment response only in classical subtype GBM. Integrative analysis of genomic and proteomic profiles challenges the notion of therapeutic inhibition of a pathway as an alternative to inhibition of the target itself. These data will facilitate the discovery of therapeutic and diagnostic target candidates, the validation of research and clinical observations and the generation of unanticipated hypotheses that can advance our molecular understanding of this lethal cancer

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Background Previous evidence indicates that adjuvant, short-course androgen deprivation therapy (ADT) improves metastasis-free survival when given with primary radiotherapy for intermediate-risk and high-risk localised prostate cancer. However, the value of ADT with postoperative radiotherapy after radical prostatectomy is unclear. Methods RADICALS-HD was an international randomised controlled trial to test the efficacy of ADT used in combination with postoperative radiotherapy for prostate cancer. Key eligibility criteria were indication for radiotherapy after radical prostatectomy for prostate cancer, prostate-specific antigen less than 5 ng/mL, absence of metastatic disease, and written consent. Participants were randomly assigned (1:1) to radiotherapy alone (no ADT) or radiotherapy with 6 months of ADT (short-course ADT), using monthly subcutaneous gonadotropin-releasing hormone analogue injections, daily oral bicalutamide monotherapy 150 mg, or monthly subcutaneous degarelix. Randomisation was done centrally through minimisation with a random element, stratified by Gleason score, positive margins, radiotherapy timing, planned radiotherapy schedule, and planned type of ADT, in a computerised system. The allocated treatment was not masked. The primary outcome measure was metastasis-free survival, defined as distant metastasis arising from prostate cancer or death from any cause. Standard survival analysis methods were used, accounting for randomisation stratification factors. The trial had 80% power with two-sided α of 5% to detect an absolute increase in 10-year metastasis-free survival from 80% to 86% (hazard ratio [HR] 0·67). Analyses followed the intention-to-treat principle. The trial is registered with the ISRCTN registry, ISRCTN40814031, and ClinicalTrials.gov, NCT00541047. Findings Between Nov 22, 2007, and June 29, 2015, 1480 patients (median age 66 years [IQR 61–69]) were randomly assigned to receive no ADT (n=737) or short-course ADT (n=743) in addition to postoperative radiotherapy at 121 centres in Canada, Denmark, Ireland, and the UK. With a median follow-up of 9·0 years (IQR 7·1–10·1), metastasis-free survival events were reported for 268 participants (142 in the no ADT group and 126 in the short-course ADT group; HR 0·886 [95% CI 0·688–1·140], p=0·35). 10-year metastasis-free survival was 79·2% (95% CI 75·4–82·5) in the no ADT group and 80·4% (76·6–83·6) in the short-course ADT group. Toxicity of grade 3 or higher was reported for 121 (17%) of 737 participants in the no ADT group and 100 (14%) of 743 in the short-course ADT group (p=0·15), with no treatment-related deaths. Interpretation Metastatic disease is uncommon following postoperative bed radiotherapy after radical prostatectomy. Adding 6 months of ADT to this radiotherapy did not improve metastasis-free survival compared with no ADT. These findings do not support the use of short-course ADT with postoperative radiotherapy in this patient population

Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

Funder: NCI U24CA211006Abstract: The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) curated consensus somatic mutation calls using whole exome sequencing (WES) and whole genome sequencing (WGS), respectively. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, which aggregated whole genome sequencing data from 2,658 cancers across 38 tumour types, we compare WES and WGS side-by-side from 746 TCGA samples, finding that ~80% of mutations overlap in covered exonic regions. We estimate that low variant allele fraction (VAF < 15%) and clonal heterogeneity contribute up to 68% of private WGS mutations and 71% of private WES mutations. We observe that ~30% of private WGS mutations trace to mutations identified by a single variant caller in WES consensus efforts. WGS captures both ~50% more variation in exonic regions and un-observed mutations in loci with variable GC-content. Together, our analysis highlights technological divergences between two reproducible somatic variant detection efforts

Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial

Background Previous evidence supports androgen deprivation therapy (ADT) with primary radiotherapy as initial treatment for intermediate-risk and high-risk localised prostate cancer. However, the use and optimal duration of ADT with postoperative radiotherapy after radical prostatectomy remains uncertain. Methods RADICALS-HD was a randomised controlled trial of ADT duration within the RADICALS protocol. Here, we report on the comparison of short-course versus long-course ADT. Key eligibility criteria were indication for radiotherapy after previous radical prostatectomy for prostate cancer, prostate-specific antigen less than 5 ng/mL, absence of metastatic disease, and written consent. Participants were randomly assigned (1:1) to add 6 months of ADT (short-course ADT) or 24 months of ADT (long-course ADT) to radiotherapy, using subcutaneous gonadotrophin-releasing hormone analogue (monthly in the short-course ADT group and 3-monthly in the long-course ADT group), daily oral bicalutamide monotherapy 150 mg, or monthly subcutaneous degarelix. Randomisation was done centrally through minimisation with a random element, stratified by Gleason score, positive margins, radiotherapy timing, planned radiotherapy schedule, and planned type of ADT, in a computerised system. The allocated treatment was not masked. The primary outcome measure was metastasis-free survival, defined as metastasis arising from prostate cancer or death from any cause. The comparison had more than 80% power with two-sided α of 5% to detect an absolute increase in 10-year metastasis-free survival from 75% to 81% (hazard ratio [HR] 0·72). Standard time-to-event analyses were used. Analyses followed intention-to-treat principle. The trial is registered with the ISRCTN registry, ISRCTN40814031, and ClinicalTrials.gov , NCT00541047 . Findings Between Jan 30, 2008, and July 7, 2015, 1523 patients (median age 65 years, IQR 60–69) were randomly assigned to receive short-course ADT (n=761) or long-course ADT (n=762) in addition to postoperative radiotherapy at 138 centres in Canada, Denmark, Ireland, and the UK. With a median follow-up of 8·9 years (7·0–10·0), 313 metastasis-free survival events were reported overall (174 in the short-course ADT group and 139 in the long-course ADT group; HR 0·773 [95% CI 0·612–0·975]; p=0·029). 10-year metastasis-free survival was 71·9% (95% CI 67·6–75·7) in the short-course ADT group and 78·1% (74·2–81·5) in the long-course ADT group. Toxicity of grade 3 or higher was reported for 105 (14%) of 753 participants in the short-course ADT group and 142 (19%) of 757 participants in the long-course ADT group (p=0·025), with no treatment-related deaths. Interpretation Compared with adding 6 months of ADT, adding 24 months of ADT improved metastasis-free survival in people receiving postoperative radiotherapy. For individuals who can accept the additional duration of adverse effects, long-course ADT should be offered with postoperative radiotherapy. Funding Cancer Research UK, UK Research and Innovation (formerly Medical Research Council), and Canadian Cancer Society